. Men who undergo bilateral orchidectomy have a rapid and progressive loss of lumbar spine integral bone with time from orchidectomy (Stepan et al., 1989). In men with hyperprolactinaemic hypogonadism restoration of normal testicular function is assocated with a significant increase in cortical BMD (Greenspan et al., 1986) . Siilarly, restoration of normal serum testosterone in men with idiopathic hypogonadotrophic hypogonadism is also associated with a significant increase in cortical BMD (Finkelstein et al., 1989 puted tomography. There was, however, a significant reduction in cortical and trabecular BMD in women with chemotherapy-induced premature ovarian failure compared with similarly treated women with normal ovarian function.
reduction in both cortical and trabecular BMD. Men with a history of delayed puberty, who are effectively androgen deficient at a critical stage in their attainnt of peak bone mass, have reduced cortical and trabecular BMD (Finkelstein et al., 1992) . Men who undergo bilateral orchidectomy have a rapid and progressive loss of lumbar spine integral bone with time from orchidectomy (Stepan et al., 1989) . In men with hyperprolactinaemic hypogonadism restoration of normal testicular function is assocated with a significant increase in cortical BMD (Greenspan et al., 1986) . Siilarly, restoration of normal serum testosterone in men with idiopathic hypogonadotrophic hypogonadism is also associated with a significant increase in cortical BMD (Finkelstein et al., 1989) .
Men who receive conventional chemotherapy with mustine, vinblastine or vincristine, procarbazine and prednisolone for treatment of Hodgkin's disease become azoospermic with raised serum follicle-stimulating hormone (FSH) levels, indicating chemotherapy-induced damage to the germinal epithelium (Whitehead et al., 1982; Tsatsoulis et al., 1987) . Leydig cell function is more difficult to categorise. The serum testosterone level and free testosterone index have been shown to be normal (Tsatsoulis et al., 1987) , but the serum luteinising hormone (LH) concentration is raised, suggesting a subtle form of Leydig cell dysfunction (Whitehead et al., 1982; Tsatsoulis et al., 1987) . However, testosterone response to a large bolus dose of human chorionic gonadotrophin (hCG) was found to be normal (Tsatsoulis et al., 1987) . Kreuser et al. (1992) puted tomography. There was, however, a significant reduction in cortical and trabecular BMD in women with chemotherapy-induced premature ovarian failure compared with similarly treated women with normal ovarian function.
We have studied BMD in 29 men in complete remission following treatment of Hodgkin's disease. We have studied the relationship between serum testosterone and BMD, and the effect on BMD of time elapsed since completion of chemotherapy, type of chemotherapy received and number of cycles of chemotherapy.
S and methods
We studied 29 caucasian men who had previously received chemotherapy for Hodg9in's disease. The study subjects were drawn from 50 consecutive men who presented to the Medical Oncology Dertment at Christie Hospital with newly diagosed Hodgkin's diseas and who were randomised to receive MVPP or hybrid chemotherapy. The 50 men took part in a study investigating the effects of MVPP and hybrid chemotherapy on gonadal function, and 29 of these men consented to have measurements of BMD performed. In the 29 men who underwent measurements of BMD, age at onset of chemotherapy was 31.0 ± 1.9 (mean + standard error, range 16.4-54.0) years. Twelve men had received a mean of 7.5 (range 5-8) cycles of MVPP (mustine 10 mg i.v. and vinblasin 10 mg i.v. on days 1 and 8 with procarbazine 150 mg daily and prednisolone 50 mg daily on days 1-14 of a 42 day cycle) and 17 men had received a mean of 7.5 (range 6-8) cycles of hybrid chemotherapy (vinblastine lOmgi.v. on day 1, with chlorambucil 1Omg daily, procarbazine 150 mg daily and prednisolone 50 mg daily on days 1-7, and etoposide 200mg m-2 i.v., viris 2 mg i.v. and doxorubicin 50 mg m-2i.v. on day 8 of a 28 day cycle). Twenty-four men received radiotherapy (15 to chest and mediastinum, eight to neck and one to axilla) but none in a radiation field which included the testes or the parts of the skeleton studied. All men were in complete remission at the time of study, and all had azoospermia.
Blood samples were taken for estimation of serum testosterone, sex hormone-binding globulin (SHBG), LH and FSH. Seven men had blood samples taken on one occasion, 19 on two occasions and three on three occasions. There were therefore a total of 54 blood samples taken 2.7 ± 0.2 (range 0.1 to 6.8) years after completion of chemotherapy. In the 22 men who had more than one blood sample taken, the samples were taken 1.6 ± 0.1 (range 0. (Wahner et al., 1977) . Scanning was performed at two sites: ultradistal, giving a measure of integral bone, and proximal, giving a measure of cortical bone. Data from only the proximal site were used in the study. Bone mineral content (BMC) was measured in gcm-. The precision of BMC measurement in our department by SPA at the proximal site is 1%.
SPA provides a measure of bone mineral per unit length of forearm bones but takes no account of the width or depth of the bone. Thomsen et al. (1986) have shown that BMC/lean body mass (LBM) is an effective correction for both height and weight. LBM was caculated according to the equation of Boddy et al. (1972) and has previously been shown to fit closely with LBM measured by dual photon absorptiometry . We used both BMC and BMC/ LBM measurements in the men studied.
Dual energy X-ray absorptometry (DXA) Measurement of integral (cortical and trabecular) bone was made in the lumbar spine (L2-L4) and the right femoral neck using a Lunar DPX-L scanner (Lunar Corporation, Madison, WI, USA) (Cullum et al., 1989) . Mean BMD was measured in gcMn2.
Precision of the measurement in our department is 0.5% in the spine and 2.5% in the femoral neck.
To assess whether the measurements made in each individual were normal or reduced, the values were expressed as Z (standard deviation) scores (Parfitt, 1990) compared with appropriate normal reference data matched for age and sex. The DXA Z-scores were also weight corrected. The data published by Thomsen et al. (1986) were used for SPA, and data provided by the manufacturer (Lunar Corporation) (Laskey et al., 1992) were used for DXA. These published reference data were confirmed to be appropriate for men from our local population using data derived from a study in which individuals were drawn at random from the age and sex register of a local medical practice and had BMD measurements performed (Adams et al., 1992 There was a significant positive correlation between serum testosterone and Z-score of lumbar spine BMD (r = 0.37, P=0.02) and of femoral neck BMD (r=0.41, P<0.02). There was a significant negative correlation between serum testosterone and Z-score of forearm BMC (r=-0.45, P<0.01) but a non-significant positive correlation between serum testosterone and Z-score of forearm BMC/LBM (r=0.21, P=0.14). There was no significant correlation between Z-score at any site and serum SHBG, LH or FSH. There was a significant positive correlation between serum testosterone/SHBG ratio and Z-score of femoral neck BMD (r= 0.44, P<0.01) and a significant negative correlation between serum testosterone/SHBG ratio and Z-score of forearm BMC (r = -0.31, P<0.05). There was no significant correlation between this ratio and Z-score of lumbar spine BMD or of forearm BMC/LBM.
There was no significant difference in Z-score at any site between those men who had received MVPP (n = 12) and those who had received hybrid (n = 17) chemotherapy.
There was no significant difference in Z-score at any site between those men who had received eight cycles (n = 20) and those who had received 5-7 cycles (n = 9) of chemotherapy. kin's disaw (Whitehead et al., 1982; Tsatsoulis et al., 1987) , indicating that Leydig cell function had been compromised in at least some of the men studied. (Redman et al., 1988) . In these women the reduction in cortical bone mass appears to be independent of chemotherapy-induced impairment of ovarian function and hence hypogonadism. The reduction of integral BMD in addition to cortical BMC in women with premature ovarian failure following treatment of Hodgkin's disease (Redman et al., 1988) suggests that the reduced integral BMD is due to hypogonadism. However, the possibility that cortical and integral bone respond differently to hypogonadism is not in agreement with the finding that both cortical and integral BMD are reduced in men with severe hypogonadism due to idiopathic hypogonadotrophic hypogonadism (Finkelsstein et al., 1987) or hyperprolaminaemia (Greenspan et al., 1986) . Furthemore, if the osteopenia that we have demonstrated was due to hypogonadism, it might be expected that BMD would be further reduced with increasing time elapsed since completion of chemotherapy, and hence a longer duration of hypogonadism, but this is not the case in the men studied. BMC, measured by SPA, provides a measure of bone mineral per unit length of forearm bones only, and takes no account of the width or depth of the bone; BMC/LBM can be used to provide an effective correction for both height and weight (Thomsen et al., 1986) . The significant negative correlation between serum testosterone and Z-score of forearm cortical BMC, in contrast to the significant positive correlaton between serum testosterone and Z-score of lumbar spine and femoral neck integral BMD, may be due to a confounding effect of the size of the subject on the forearm cortical BMC. This is supported by the finding of a positive (but non-significant) correlation between serum testosterone and forearm cortical BMC when corrected for LBM, in accordance with the direction of the correlation between serum testosterone and Z-score at lumbar spine and femoral neck. This change in direction of the correlation from negative to positive when BMC is corrected for LBM may be due to the rather surprising and unexplained significant negative correlation between serum testosterone and LBM (r =-0.36, P < 0.05).
Dbcsiom
Short-term treatment of rats with methotrexate and doxorubicin has been shown to cause a significant reduction in vertebral trabecular bone volume and in bone formation rate (Friedlaender et al., 1984) , raising the possibility that chemotherapeutic agents may have a direct effect on bone turnover, and hence BMD, in man. Furthermore, glucocorticoid treatment can cause osteopenia (Baylink. 1983) , and the steroid component of the chemotherapeutic regimens could be considered as a possible cause of osteopenia.
In conclusion, we have demonstrated that men who have received chemotherapy for Hodgkin's disease have reduced BMD. Possible causes include mild hypogonadism secondary to impaired Leydig cell function following chemotherapy, a direct effect of chemotherapy on bone, an effect of administration of high-dose glucocorticoid, or an effect of Hodgkin's disease per se. A reduction in femoral neck BMD by one standard deviation from the age-adjusted mean has been shown to increase the risk of hip fracture by a factor of 2.6 in women over the age of 65 years (Cummings et al., 1993 
